Get the Stockscreener App
7.87
0.25%
0.02
Regulus Therapeutics Inc stock is traded at $7.87, with a volume of 1.65M.
It is up +0.25% in the last 24 hours and up +360.23% over the past month.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$7.85
Open:
$7.83
24h Volume:
1.65M
Relative Volume:
0.94
Market Cap:
$543.15M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-4.981
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
+0.25%
1M Performance:
+360.23%
6M Performance:
+435.37%
1Y Performance:
+249.78%
1-Day Range:
$7.8112
$7.92
1-Week Range:
$7.801
$7.92
52-Week Range:
$0.8301
$8.20
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858-202-6300
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Compare RGLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
7.87 | 543.15M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Mar-18-24 | Initiated | Leerink Partners | Outperform |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PR Newswire
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancor - Morningstar
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc.RGLS - The Malaysian Reserve
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha
Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target - marketscreener.com
India’s Competition Commission Clears J&K Bank in Antitrust Case - PYMNTS.com
Top Midday Gainers - marketscreener.com
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull
Novartis to buy Regulus Therapeutics for up to $1.7 billion - MSN
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters
Novartis to Acquire Regulus Therapeutics in Potential $1.7B Deal - Contract Pharma
Generac, Regulus Therapeutics, Garmin - TradingView
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis By Stocktwits - Investing.com India
Regulus Therapeutics' stock price doubles on Novartis's buyout offer - TradingView
Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus
Latham & Watkins Advises Regulus Therapeutics in Acquisition by Novartis AG - Latham & Watkins LLP
Swiss pharma giant Novartis to acquire San Diego biotech Regulus in $1.7B deal - Axios
Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement - The Globe and Mail
Novartis to acquire Regulus Therapeutics for up to $1.7 billion - PharmaLive
Regulus Announces Merger Agreement with Novartis - TipRanks
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):